Recruiting

Testing a new medication for moderate to severe plaque psoriasis

Plain-English translation of NCT07130604 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This clinical trial is testing a new medication called to see if it can help people with moderate to severe plaque psoriasis—a skin condition where thick, red patches covered with scales develop on the skin. Researchers want to find out whether this medication works better than a placebo (a dummy pill with no active ingredient) and whether it is safe to use.

Plaque psoriasis can be difficult to treat and significantly impact quality of life. This trial is exploring whether this new treatment offers a better option for people whose psoriasis is too severe to manage with milder treatments alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with plaque psoriasis that has been stable for at least 6 months before joining
your psoriasis covers at least 10% of your body surface area
your psoriasis is moderate to severe and severe enough to need systemic (whole-body) treatment
you are willing to sign a consent form and follow all study procedures
your blood tests, chemistry panels, and urine tests are basically normal

You likely don't qualify if…

you have a different type of psoriasis, such as erythrodermic, pustular, or guttate psoriasis
you have active or latent tuberculosis or signs of tuberculosis infection
you have or recently had herpes zoster (shingles) or herpes simplex infections
you have other skin conditions like eczema that would make it hard to measure how well the treatment works
you have other health conditions that your doctor thinks would make participation unsafe

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication or a placebo, and neither you nor the researchers will know which one you're getting (this is called a double-blind study). You will visit the research center multiple times for check-ups, skin assessments, and blood tests to see how the medication affects your psoriasis. The study involves about 390 participants across multiple centers and will track how well the treatment works and what side effects, if any, occur.

AI-generated summary from trial data · Jun 14, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University People's Hospital, Beijing, Beijing Municipality

Testing a new medication for moderate to severe plaque psoriasis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Contact the research team directly

Interested in joining?